Efalizumab is a recombinant humanized murine monoclonal antibody against CD11a, approved for the treatment of plaque psoriasis. However, recent reports suggest that it also may be effective in the treatment of severe atopic dermatitis (AD).
|Tidsskrift||Journal of the European Academy of Dermatology and Venereology : JEADV|
|Status||Udgivet - 1 jul. 2010|